ABO and RhD blood groups as contributors to dyslipidaemia - a cross-sectional study. 2025

Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
Department of Medical Biosciences, Clinical Chemistry, Umeå University, Building 6M 2:Nd Floor, 901 85, Umeå, Sweden. malin.mickelsson@umu.se.

BACKGROUND The ABO blood group system has shown an association with cardiovascular disease. The susceptibility to CVD is proposed to be partly mediated by dyslipidaemia in non-O individuals. Previous studies are scarce for the RhD blood group, but we recently showed that RhD - young individuals are associated with subclinical atherosclerosis. Hence, we sought to examine whether the ABO blood groups and RhD factor are associated with dyslipidaemia. METHODS All participants were part of the VIPVIZA study, including 3532 individuals with available plasma lipid levels. Lipids were assessed as total, LDL, HDL, remnant, non-HDL cholesterol and triglycerides. Information about ABO and RhD was retrieved by linking VIPVIZA with the SCANDAT-3 database, where 85% of VIPVIZA participants were registered. RESULTS For the ABO blood groups, no significant differences in lipid levels between non-O and O individuals were seen. In 40-year-old males, RhD - individuals compared to RhD + had higher levels of non-HDL cholesterol, LDL cholesterol, and remnant cholesterol, with ratios of geometric means of 1.21 (CI95% 1.03; 1.43), 1.20 (1.02; 1.41) and 1.38 (1.00; 1.92), respectively. No differences in lipid levels depending on the RhD blood group were seen in women or the older age groups. CONCLUSIONS Our study indicates that younger RhD - men have increased non-HDL, LDL, and remnant cholesterol levels. Thus, the RhD blood group, but not ABO, seems to be associated with dyslipidaemia and may act as a future possible risk marker of cardiovascular disease.

UI MeSH Term Description Entries

Related Publications

Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
December 2017, BMJ open,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
April 2021, International journal of clinical practice,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
March 2018, Turkish archives of otorhinolaryngology,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
January 2024, Pakistan journal of medical sciences,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
January 2021, Oral health & preventive dentistry,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
September 2012, BJOG : an international journal of obstetrics and gynaecology,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
August 1958, The American journal of psychiatry,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
January 2024, European journal of microbiology & immunology,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
October 2020, Medicine,
Malin Mickelsson, and Kim Ekblom, and Kristina Stefansson, and Per Liv, and Anders Själander, and Ulf Näslund, and Johan Hultdin
July 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Copied contents to your clipboard!